PamGene International B.V.

Company description

PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene’s projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. Our collaborators apply our technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity.

Three unique aspects of PamGene’s proprietary biomarker technology are:
The empowerment of a completely new way of translational biomarker development.
The emphasis on evidence-based medicine development by delivering and supporting scientific hypotheses: Understanding the on and off-target activities of a medicine is key.
Fully developed CE marked instrumentation for testing in the clinic is available. Testing in a CLIA certified laboratory can be organized.

Products and services

Classic diagnostics determine the nature of a disease but give little or no information on how patients will respond to treatment. PamGene’s Matching Medicine approach ultimately aims to provide medical oncologists with valuable additional data to create the best plan for a particular patient, guiding the selection of likely responders, and avoiding non-responders experiencing unnecessary side effects and lost time.

Patient:drug response data, known as a PamGene Index (PamInDx) patient profile, have the potential to provide valuable predictive information to facilitate the matching of a medicine to a specific patient prior to drug administration. PamGene’s ambition is for Matching Medicines™ to become part of routine clinical practice.

In summary, our Matching Medicines technology and approach aims to:

Help stratify patients for clinical trials
Contribute to the often difficult treatment decisions that doctors have to make based on information from limited clinical trials
Select the right drug for the right patient in those cases where a choice of kinase inhibitors is available (e.g. in leukaemia such as CML)
Help avoid unnecessary treatment of patients with drugs, avoiding side effects and avoiding unnecessary costs to the healthcare system